Skip to content
Screener

Operating Cash Flow at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$24.02M+52.0%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-$54.07M+9.7%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$52.57M+18.8%
Cytokinetics logo
CytokineticsCYTK
-$159.84M-24.6%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
-$57.31M+25.7%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$197.28M+1.0%

Other financials

Income statement

See full
Revenue$243.6M+55.4%
Gross profit$220.0M+59.2%
Operating income$27.2M+34.9%
Net income$25.4M+42.6%
EPS (diluted)$0.30+30.4%

Balance sheet

See full
Cash & equivalents$175.7M-8.5%
Total debt$8.9M-8.9%
Total equity$654.1M+32.1%
Total assets$896.1M+35.5%

Cash flow

See full
CapEx$663.0K+302%
Free cash flow$46.5M+66.6%

Valuation

See full
Market cap$5.97B+146%
Enterprise value$5.8B+159%
P/E74×-432×
P/S7.1×+2.5×

Profitability

See full
Gross margin89.8%+3.9pp
Operating margin11.9%+11.1pp
Net margin9.6%+8.7pp
FCF margin21.7%+8.8pp

Returns & leverage

See full
Return on equity14%+13.0pp
Debt / equity0.0×
Current ratio3.9×+0.3×

Where this comes from

Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The source filing: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:17 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-087545
Line itemSix Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Accrued expenses, accrued collaboration expenses and other current liabilities20,7449,502
Operating lease liabilities(1,151)(1,777)
Other long-term liabilities15,4067,439
Net cash provided by operating activities97,39450,414
Cash flows from investing activities:
Purchases of property and equipment(824)(264)
Purchases of short-term investments(287,031)(129,793)
Proceeds from the maturities of short-term investments182,35974,633

Item 1. Financial Statements (unaudited)

FAQ

What is Kiniksa Pharmaceuticals International, plc's operating cash flow?
Kiniksa Pharmaceuticals International, plc (KNSA) reported operating cash flow of $47.2M in Q2 2026.
How has Kiniksa Pharmaceuticals International, plc's operating cash flow changed year-over-year?
Kiniksa Pharmaceuticals International, plc's operating cash flow increased by 68.0% year-over-year, from $28.09M to $47.2M.
What is the long-term trend for Kiniksa Pharmaceuticals International, plc's operating cash flow?
Over 3 years (2021 to 2025), Kiniksa Pharmaceuticals International, plc's operating cash flow has grown at a 3.0% compound annual growth rate (CAGR), from -$126.3M to $137.99M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.

Ask your AI about Kiniksa Pharmaceuticals International, plc's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude